Evidence map›Paper›PMID 40574058›Full record

ReviewPharmaceutics2025

Advances in Transdermal Drug Delivery Systems and Clinical Applications in Inflammatory Skin Diseases.

Sizhuo Liu, Tinghan Deng, Hongbin Cheng, Jun Lu, Jingping Wu

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sizhuo LiuSchool of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610032, China.
Tinghan DengSchool of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610032, China.ORCID 0000-0002-2331-5780
Hongbin ChengTraditional Chinese Medicine Hospital of Sichuan Province, Chengdu 610072, China.
Jun LuCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 610032, China.ORCID 0000-0003-1625-8682
Jingping WuTraditional Chinese Medicine Hospital of Sichuan Province, Chengdu 610072, China.

Funding

Sichuan Provincial Administration of Traditional Chinese Medicine 2023zd019Sichuan Provincial Department of Science and Technology 2024YFFK0165the Key Research and Development Program (Major Science and Technology Special Project) of Sichuan Provincial Department of Science and Technology No. 2022YFS0413the Key Research and Development Program (Major Science and Technology Special Project) of Sichuan Provincial Department of Science and Technology No. 2022YFS0416
6 · The paper itself

Abstract

Inflammatory skin diseases are highly prevalent conditions characterized by complex immune responses that result in skin tissue damage and pain, significantly impacting patients' physical health. Traditional therapeutic approaches, including oral administration and injections, continue to exhibit inherent limitations. Consequently, there is growing interest in exploring alternative drug delivery systems that offer more effective, targeted, and patient-friendly therapeutic options. Transdermal administration emerges as a promising solution for managing inflammatory skin diseases, facilitating sustained drug release, and reducing the frequency of dosing. This review provides a comprehensive overview of the skin barrier and critically summarizes clinically adopted transdermal drug delivery systems (TDDSs), including sonophoresis, iontophoresis, chemical penetration enhancers, and electroporation. Particular emphasis is placed on emerging advances in microneedle- and nanocarrier-facilitated transdermal delivery strategies. Moreover, the article synthesizes recent fundamental evidence regarding the application of TDDSs in the treatment of atopic dermatitis, psoriasis, and acne. This review examines fundamental research evaluating various transdermal drug delivery systems for the treatment of major inflammatory skin diseases, with an emphasis on their mechanisms of action, advantages, challenges, and future directions. Transdermal drug delivery systems hold the potential to deliver more efficient and safer treatment and management strategies for patients afflicted with inflammatory skin diseases.

Indexed as

acneatopic dermatitisinflammationnanocarrierpsoriasisskintransdermal drug delivery system

Identifiers

PMID40574058
PMCPMC12195946

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.